SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Unquoted Biotechs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI5/9/2006 12:10:25 PM
   of 253
 
Roche Buys Test Drug
For 'Good' Cholesterol
By a WALL STREET JOURNAL Staff Reporter
May 9, 2006; Page D2

Roche Holding AG said it bought another experimental drug to raise "good," or HDL, cholesterol, boosting its presence in the emerging field.

Roche acquired exclusive rights to Trimeric Apo A-I, an early-stage preclinical compound being developed by closely held Danish biotech firm Borean Pharma, for an undisclosed sum. The compound is a version of the naturally occurring protein apolipoprotein A-I, which is the major protein component of high-density lipoprotein HDL.

Roche licensed rights to another HDL cholesterol drug from Japan Tobacco Inc. in October 2004. Pfizer Inc. is currently seen as the leader in the development of HDL-raising drugs, which some researchers predict will be the next big thing in preventing heart attacks and strokes.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News